Workflow
Drug candidates (implied in biotech context)
icon
Search documents
Doximity: Strong Quarter Overshadowed By Policy-Driven Budget Uncertainty (NYSE:DOCS)
Seeking Alpha· 2025-12-08 13:46
Group 1 - Doximity, Inc. reported a 2Q26 non-GAAP EPS of $0.45, beating estimates by approximately $0.07 [1] - Revenue for Doximity was $168.5 million, exceeding consensus expectations by $10.91 million and reflecting a year-over-year increase of 23.2% [1]